Asset profile
IBC-Ab002
Monoclonal antibody
Evidence outlook · lead readout
NCT05551741 · Alzheimer's Disease
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT05551741: This is a randomized, blinded, placebo-controlled study, which is a sound design, but every reported measure is a safety check rather than a memory or cognition outcome, each active dose group had only 6 participants, and no statistical comparison between doses and placebo was reported for any measure.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.